The Effects of Statin Medications on Aerobic Exercise Capacity and Training Adaptations

Sports Medicine

Volumn 44, Issue 11, 2014, Pages 1519-1530

  Murlasits, Zsolt ^a   Radák, Zsolt ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TERPENE;

ADAPTATION; ANAEROBIC THRESHOLD; ANIMAL; BIOSYNTHESIS; DRUG EFFECTS; EXERCISE; EXERCISE TOLERANCE; HUMAN; METABOLISM; MITOCHONDRION; MUSCLE STRENGTH; PHYSIOLOGY; RESISTANCE TRAINING; SKELETAL MUSCLE;

ADAPTATION, PHYSIOLOGICAL; ANAEROBIC THRESHOLD; ANIMALS; CHOLESTEROL; EXERCISE TOLERANCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MITOCHONDRIA; MUSCLE STRENGTH; MUSCLE, SKELETAL; PHYSICAL CONDITIONING, HUMAN; RESISTANCE TRAINING; TERPENES;

EID: 84931044932     PISSN: 01121642     EISSN: 11792035     Source Type: Journal    
DOI: 10.1007/s40279-014-0224-4     Document Type: Review

References (98)

1. Bhardwaj S, Selvarajah S, Schneider EB. Muscular effects of statins in the elderly female: a review. Clin Interv Aging. 2013;8:47–59.
2. Health, United States 2010 [homepage on the Internet]. CDC. 2010 [cited 2013]. Available from: http://www.cdc.gov/nchs/data/hus/2010/fig17.pdf.
3. Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Lloyd-Jones DM, Blum CB, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2013.
4. Baker SK, Tarnopolsky MA. Statin myopathies: pathophysiologic and clinical perspectives. Clin Invest Med. 2001;24(5):258–72.
5. Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients: the PRIMO study. Cardiovasc Drugs Ther. 2005;19(6):403–14.
6. Buettner C, Lecker SH. Molecular basis for statin-induced muscle toxicity: implications and possibilities. Pharmacogenomics. 2008;9(8):1133–42.
7. Di Stasi SL, MacLeod TD, Winters JD, Binder-Macleod SA. Effects of statins on skeletal muscle: a perspective for physical therapists. Phys Ther. 2010;90(10):1530–42.
8. Dirks AJ, Jones KM. Statin-induced apoptosis and skeletal myopathy. Am J Physiol Cell Physiol. 2006;291(6):C1208–12.
9. El-Salem K, Ababneh B, Rudnicki S, Malkawi A, Alrefai A, Khader Y, et al. Prevalence and risk factors of muscle complications secondary to statins. Muscle Nerve. 2011;44(6):877–81.
10. Franc S, Dejager S, Bruckert E, Chauvenet M, Giral P, Turpin G. A comprehensive description of muscle symptoms associated with lipid-lowering drugs. Cardiovasc Drugs Ther. 2003;17(5–6):459–65.
11. Kearns AK, Bilbie CL, Clarkson PM, White CM, Sewright KA, O’Fallon KS, et al. The creatine kinase response to eccentric exercise with atorvastatin 10 mg or 80 mg. Atherosclerosis. 2008;200(1):121–5.
12. Mallinson JE, Constantin-Teodosiu D, Sidaway J, Westwood FR, Greenhaff PL. Blunted akt/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy. J Physiol. 2009;587(Pt 1):219–30.
13. Mohaupt MG, Karas RH, Babiychuk EB, Sanchez-Freire V, Monastyrskaya K, Iyer L, et al. Association between statin-associated myopathy and skeletal muscle damage. CMAJ. 2009;181(1–2):E11–8.
14. Reust CS, Curry SC, Guidry JR. Lovastatin use and muscle damage in healthy volunteers undergoing eccentric muscle exercise. West J Med. 1991;154(2):198–200.
15. Sacher J, Weigl L, Werner M, Szegedi C, Hohenegger M. Delineation of myotoxicity induced by 3-hydroxy-3-methylglutaryl CoA reductase inhibitors in human skeletal muscle cells. J Pharmacol Exp Ther. 2005;314(3):1032–41.
16. Sinzinger H, Wolfram R, Peskar BA. Muscular side effects of statins. J Cardiovasc Pharmacol. 2002;40(2):163–71.
17. Sirvent P, Mercier J, Lacampagne A. New insights into mechanisms of statin-associated myotoxicity. Curr Opin Pharmacol. 2008;8(3):333–8.
18. Tanaka S, Sakamoto K, Yamamoto M, Mizuno A, Ono T, Waguri S, et al. Mechanism of statin-induced contractile dysfunction in rat cultured skeletal myofibers. J Pharmacol Sci. 2010;114(4):454–63.
19. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003;289(13):1681–90.
20. Tomlinson SS, Mangione KK. Potential adverse effects of statins on muscle. Phys Ther. 2005;85(5):459–65.
21. Charlton-Menys V, Durrington PN. Human cholesterol metabolism and therapeutic molecules. Exp Physiol. 2008;93(1):27–42.
22. Kobayashi M, Chisaki I, Narumi K, Hidaka K, Kagawa T, Itagaki S, et al. Association between risk of myopathy and cholesterol-lowering effect: a comparison of all statins. Life Sci. 2008;82(17–18):969–75.
23. Mascitelli L, Pezzetta F. Physical activity in statin-treated patients. Int J Cardiol. 2009;134(1):136–7.
24. Parker BA, Thompson PD. Effect of statins on skeletal muscle: exercise, myopathy, and muscle outcomes. Exerc Sport Sci Rev. 2012;40(4):188–94.
25. Bouitbir J, Charles AL, Rasseneur L, Dufour S, Piquard F, Geny B, et al. Atorvastatin treatment reduces exercise capacities in rats: involvement of mitochondrial impairments and oxidative stress. J Appl Physiol. 2011;111(5):1477–83.
26. Opie LH. Exercise-induced myalgia may limit the cardiovascular benefits of statins. Cardiovasc Drugs Ther. 2013;27(6):569–72.
27. Meador BM, Huey KA. Statin-associated myopathy and its exacerbation with exercise. Muscle Nerve. 2010;42(4):469–79.
28. Meador BM, Huey KA. Statin-associated changes in skeletal muscle function and stress response after novel or accustomed exercise. Muscle Nerve. 2011;44(6):882–9.
29. Semple SJ. Statin therapy, myopathy and exercise: a case report. Lipids Health Dis. 2012;16(11):40.
30. Sinzinger H, O’Grady J. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br J Clin Pharmacol. 2004;57(4):525–8.
31. Thompson PD, Zmuda JM, Domalik LJ, Zimet RJ, Staggers J, Guyton JR. Lovastatin increases exercise-induced skeletal muscle injury. Metabolism. 1997;46(10):1206–10.
32. Thompson PD, Parker B. Statins, exercise, and exercise training. J Am Coll Cardiol. 2013;62(8):715–6.
33. Lim S, Despres JP, Koh KK. Prevention of atherosclerosis in overweight/obese patients: in need of novel multi-targeted approaches. Circ J. 2011;75(5):1019–27.
34. Monda KL, Ballantyne CM, North KE. Longitudinal impact of physical activity on lipid profiles in middle-aged adults: the atherosclerosis risk in communities study. J Lipid Res. 2009;50(8):1685–91.
35. Chomistek AK, Chiuve SE, Jensen MK, Cook NR, Rimm EB. Vigorous physical activity, mediating biomarkers, and risk of myocardial infarction. Med Sci Sports Exerc. 2011;43(10):1884–90.
36. Veiga OL, Gomez-Martinez S, Martinez-Gomez D, Villagra A, Calle ME, Marcos A, et al. Physical activity as a preventive measure against overweight, obesity, infections, allergies and cardiovascular disease risk factors in adolescents: AFINOS study protocol. BMC Public Health. 2009;9:475 2458-9-475.
37. Cotter KA, Lachman ME. No strain, no gain: psychosocial predictors of physical activity across the adult lifespan. J Phys Act Health. 2010;7(5):584–94.
38. Stamatakis E, Hamer M, Primatesta P. Cardiovascular medication, physical activity and mortality: cross-sectional population study with ongoing mortality follow-up. Heart. 2009;95(6):448–53.
39. Kokkinos P, Myers J. Exercise and physical activity: clinical outcomes and applications. Circulation. 2010;122(16):1637–48.
40. Barter PJ, Brandrup-Wognsen G, Palmer MK, Nicholls SJ. Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER database. J Lipid Res. 2010;51(6):1546–53.
41. Kokkinos PF, Faselis C, Myers J, Panagiotakos D, Doumas M. Interactive effects of fitness and statin treatment on mortality risk in veterans with dyslipidaemia: a cohort study. Lancet. 2013;381(9864):394–9.
42. Kokkinos P, Faselis C, Myers J, Kokkinos JP, Doumas M, Pittaras A, et al. Statin therapy, fitness, and mortality risk in middle-aged hypertensive male veterans. Am J Hypertens. 2014;27(3):422–30.
43. Mikus CR, Boyle LJ, Borengasser SJ, Oberlin DJ, Naples SP, Fletcher J, et al. Simvastatin impairs exercise training adaptations. J Am Coll Cardiol. 2013;62(8):709–14.
44. Muraki A, Miyashita K, Mitsuishi M, Tamaki M, Tanaka K, Itoh H. Coenzyme Q10 reverses mitochondrial dysfunction in atorvastatin-treated mice and increases exercise endurance. J Appl Physiol. 2012;113(3):479–86.
45. Panayiotou G, Paschalis V, Nikolaidis MG, Theodorou AA, Deli CK, Fotopoulou N, et al. No adverse effects of statins on muscle function and health-related parameters in the elderly: an exercise study. Scand J Med Sci Sports. 2013;23(5):556–67.
46. Traustadottir T, Stock AA, Harman SM. High-dose statin use does not impair aerobic capacity or skeletal muscle function in older adults. Age (Dordr). 2008;30(4):283–91.
47. Krishnan GM, Thompson PD. The effects of statins on skeletal muscle strength and exercise performance. Curr Opin Lipidol. 2010;21(4):324–8.
48. Thompson PD, Parker BA, Clarkson PM, Pescatello LS, White CM, Grimaldi AS, et al. A randomized clinical trial to assess the effect of statins on skeletal muscle function and performance: rationale and study design. Prev Cardiol. 2010;13(3):104–11.
49. Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keadle J, et al. The effect of statins on skeletal muscle function. Circulation. 2013;127(1):96–103.
50. Fuzi M, Palicz Z, Vincze J, Cseri J, Szombathy Z, Kovacs I, et al. Fluvastatin-induced alterations of skeletal muscle function in hypercholesterolaemic rats. J Muscle Res Cell Motil. 2012;32(6):391–401.
51. Parker BA, Augeri AL, Capizzi JA, Ballard KD, Troyanos C, Baggish AL, et al. Effect of statins on creatine kinase levels before and after a marathon run. Am J Cardiol. 2012;109(2):282–7.
52. Thompson PD, Clarkson PM, Rosenson RS. National lipid association statin safety task force muscle safety expert panel: an assessment of statin safety by muscle experts. Am J Cardiol. 2006;97(8A):69C–76C.
53. Scott D, Blizzard L, Fell J, Jones G. Statin therapy, muscle function and falls risk in community-dwelling older adults. QJM. 2009;102(9):625–33.
54. Coen PM, Flynn MG, Markofski MM, Pence BD, Hannemann RE. Adding exercise training to rosuvastatin treatment: influence on serum lipids and biomarkers of muscle and liver damage. Metabolism. 2009;58(7):1030–8.
55. Draeger A, Monastyrskaya K, Mohaupt M, Hoppeler H, Savolainen H, Allemann C, et al. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol. 2006;210(1):94–102.
56. Ballard KD, Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, et al. Increases in creatine kinase with atorvastatin treatment are not associated with decreases in muscular performance. Atherosclerosis. 2013;230(1):121–4.
57. Chung J, Brass EP, Ulrich RG, Hiatt WR. Effect of atorvastatin on energy expenditure and skeletal muscle oxidative metabolism at rest and during exercise. Clin Pharmacol Ther. 2008;83(2):243–50.
58. Robinson MM, Hamilton KL, Miller BF. The interactions of some commonly consumed drugs with mitochondrial adaptations to exercise. J Appl Physiol. 2009;107(1):8–16.
59. SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman L, Heath S. SLCO1B1 variants and statin-induced myopathy: a genomewide study. N Engl J Med. 2008;359:789–99.
60. Ghatak A, Faheem O, Thompson PD. The genetics of statin-induced myopathy. Atherosclerosis. 2010;210(2):337–43.
61. Mangravite LM, Engelhardt BE, Medina MW, Smith JD, Brown CD, Chasman DI, et al. A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature. 2013;502(7471):377–80.
62. Yan Z, Okutsu M, Akhtar YN, Lira VA. Regulation of exercise-induced fiber type transformation, mitochondrial biogenesis, and angiogenesis in skeletal muscle. J Appl Physiol. 2011;110(1):264–74.
63. Di Napoli P, Antonio Taccardi A, Grilli A, Spina R, Felaco M, Barsotti A. Simvastatin reduces reperfusion injury by modulating nitric oxide synthase expression: an ex vivo study in isolated working rat hearts. Cardiovasc Res. 2001;51(2):283–93.
64. Jones SP, Teshima Y, Akao M, Marban E. Simvastatin attenuates oxidant-induced mitochondrial dysfunction in cardiac myocytes. Circ Res. 2003;93(8):697–9.
65. Wright DG, Lefer DJ. Statin mediated protection of the ischemic myocardium. Vascul Pharmacol. 2005;42(5–6):265–70.
66. Bouitbir J, Charles AL, Echaniz-Laguna A, Kindo M, Daussin F, Auwerx J, et al. Opposite effects of statins on mitochondria of cardiac and skeletal muscles: a ‘mitohormesis’ mechanism involving reactive oxygen species and PGC-1. Eur Heart J. 2012;33(11):1397–407.
67. Keller-Pinter A, Murlasits Z, Szucs G, Menesi D, Puskas L, Ferdinandy P, et al. Upregulation of squalene synthase in type IIB fibers is an early response for statin treatment. Neuromusc Disord. 2011;21(9–10):744–5.
68. Westwood FR, Bigley A, Randall K, Marsden AM, Scott RC. Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity. Toxicol Pathol. 2005;33(2):246–57.
69. Sirvent P, Bordenave S, Vermaelen M, Roels B, Vassort G, Mercier J, et al. Simvastatin induces impairment in skeletal muscle while heart is protected. Biochem Biophys Res Commun. 2005;338(3):1426–34.
70. Baker SK. Molecular clues into the pathogenesis of statin-mediated muscle toxicity. Muscle Nerve. 2005;31(5):572–80.
71. Flint OP, Masters BA, Gregg RE, Durham SK. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. Toxicol Appl Pharmacol. 1997;145(1):91–8.
72. Casey PJ. Biochemistry of protein prenylation. J Lipid Res. 1992;33(12):1731–40.
73. Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest. 2002;110(3):285–8.
74. McTaggart SJ. Isoprenylated proteins. Cell Mol Life Sci. 2006;63(3):255–67.
75. Welti M. Regulation of dolichol-linked glycosylation. Glycoconj J. 2013;30(1):51–6.
76. McCarty MF. Suppression of dolichol synthesis with isoprenoids and statins may potentiate the cancer-retardant efficacy of IGF-I down-regulation. Med Hypotheses. 2001;56(1):12–6.
77. Atil B, Sieczkowsky E, Hohenegger M. Statins reduce endogenous dolichol levels in the neuroblastoma cell line SH-SY5Y. BMC Pharmacol Toxicol. 2012;13(Suppl 1):A51.
78. Laaksonen R, Jokelainen K, Sahi T, Tikkanen MJ, Himberg JJ. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin Pharmacol Ther. 1995;57(1):62–6.
79. Paiva H, Thelen KM, Van Coster R, Smet J, De Paepe B, Mattila KM, et al. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther. 2005;78(1):60–8.
80. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol. 2007;49(23):2231–7.
81. Passi S, Stancato A, Aleo E, Dmitrieva A, Littarru GP. Statins lower plasma and lymphocyte ubiquinol/ubiquinone without affecting other antioxidants and PUFA. Biofactors. 2003;18(1–4):113–24.
82. Schaefer WH, Lawrence JW, Loughlin AF, Stoffregen DA, Mixson LA, Dean DC, et al. Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats. Toxicol Appl Pharmacol. 2004;194(1):10–23.
83. Vaughan RA, Garcia-Smith R, Bisoffi M, Conn CA, Trujillo KA. Ubiquinol rescues simvastatin-suppression of mitochondrial content, function and metabolism: implications for statin-induced rhabdomyolysis. Eur J Pharmacol. 2013;711(1–3):1–9.
84. Caso G, Kelly P, McNurlan MA, Lawson WE. Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol. 2007;99(10):1409–12.
85. Deichmann RE, Lavie CJ, Dornelles AC. Impact of coenzyme Q-10 on parameters of cardiorespiratory fitness and muscle performance in older athletes taking statins. Phys Sportsmed. 2012;40(4):88–95.
86. Ownby SE, Hohl RJ. Farnesol and geranylgeraniol: prevention and reversion of lovastatin-induced effects in NIH3T3 cells. Lipids. 2002;37(2):185–92.
87. Nishimoto T, Ishikawa E, Anayama H, Hamajyo H, Nagai H, Hirakata M, et al. Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs. Toxicol Appl Pharmacol. 2007;223(1):39–45.
88. Johnson TE, Zhang X, Bleicher KB, Dysart G, Loughlin AF, Schaefer WH, et al. Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone. Toxicol Appl Pharmacol. 2004;200(3):237–50.
89. Sirvent P, Fabre O, Bordenave S, Hillaire-Buys D, De Raynaud Mauverger E, Lacampagne A. Muscle mitochondrial metabolism and calcium signaling impairment in patients treated with statins. Toxicol Appl Pharmacol. 2012;259(2):263–8.
90. Hubal MJ, Reich KA, De Biase A, Bilbie C, Clarkson PM, Hoffman EP, et al. Transcriptional deficits in oxidative phosphorylation with statin myopathy. Muscle Nerve. 2011;44(3):393–401.
91. De Pinieux G, Chariot P, Ammi-Said M, Louarn F, Lejonc JL, Astier A, et al. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol. 1996;42(3):333–7.
92. Phillips PS, Phillips CT, Sullivan MJ, Naviaux RK, Haas RH. Statin myotoxicity is associated with changes in the cardiopulmonary function. Atherosclerosis. 2004;177(1):183–8.
93. Schick BA, Laaksonen R, Frohlich JJ, Paiva H, Lehtimaki T, Humphries KH, et al. Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin. Clin Pharmacol Ther. 2007;81(5):650–3.
94. Stringer HA, Sohi GK, Maguire JA, Cote HC. Decreased skeletal muscle mitochondrial DNA in patients with statin-induced myopathy. J Neurol Sci. 2013;325(1–2):142–7.
95. Bouitbir J, Daussin F, Charles AL, Rasseneur L, Dufour S, Richard R, et al. Mitochondria of trained skeletal muscle are protected from deleterious effects of statins. Muscle Nerve. 2012;46(3):367–73.
96. Bell DS. Resolution of statin-induced myalgias by correcting vitamin D deficiency. South Med J. 2010;103(7):690–2.
97. Gupta A, Thompson PD. The relationship of vitamin D deficiency to statin myopathy. Atherosclerosis. 2011;215(1):23–9.
98. Shewmon DA, Craig JM. Creatine supplementation prevents statin-induced muscle toxicity. Ann Intern Med. 2010;153(10):690–2.